Condition
    Moderate Evidence
    Effectiveness 3/5

    Black Seed Oil for High Cholesterol (Dyslipidemia)

    Meta-analyses of randomised trials report reductions in total and LDL cholesterol and triglycerides with Nigella sativa, typically over 8-12 weeks. Reductions are meaningful for mild dyslipidaemia and modest against pharmacological standards.

    Overview

    Nigella sativa — black seed — has accumulated a genuinely interesting body of randomised trial evidence for lipids. Meta-analyses of trials in metabolic and diabetic populations report reductions in total cholesterol, LDL and triglycerides, with ground seed powder generally outperforming the oil for LDL and the oil doing more for HDL. The caveats are substantial. Trials are small, mostly conducted in Middle Eastern and South Asian populations, short in duration, and highly variable in preparation and thymoquinone content — which means the dose that worked in one trial may not exist in the product on your shelf. The direction of effect is consistent enough to call this likely; the magnitude is not reliably predictable.

    Verdict

    Likely effective

    Meta-analyses of small randomised trials show reductions in total cholesterol, LDL and triglycerides alongside modest glycaemic improvements. Preparation and thymoquinone content vary widely and long-term data are absent.

    How It Works

    Thymoquinone is the principal active constituent and appears to act on several lipid pathways at once. It weakly inhibits HMG-CoA reductase — the enzyme statins target, though far less potently — reducing endogenous cholesterol synthesis, and it upregulates hepatic LDL receptor expression, increasing clearance of circulating LDL. A second set of effects runs through PPAR-alpha and AMPK activation, which raise fatty acid oxidation and reduce hepatic triglyceride output. Thymoquinone is also a potent antioxidant that reduces LDL oxidation, and the seed provides fibre and unsaturated fatty acids that modestly limit intestinal cholesterol absorption. Overlapping mechanisms plausibly explain why effects appear across the whole panel rather than a single marker.

    Pathways involved

    Weak HMG-CoA reductase inhibition
    Hepatic LDL receptor upregulation
    PPAR-alpha and AMPK activation
    Reduced LDL oxidation
    Reduced intestinal cholesterol absorption
    Anti-inflammatory signalling

    Dosing & Protocol

    ScenarioDoseFormTiming
    Oil, trial range1-3 g (about 1-3 mL) dailyCold-pressed black seed oilSplit, with meals
    Ground seed powder1-2 g dailyGround Nigella sativa seedWith meals
    Standardised extractProviding 30-60 mg thymoquinone dailyStandardised extract capsuleWith meals
    Typical trial duration8-12 weeksAnyRecheck lipids after
    1. 1

      Choose the form to match your panel· Before starting

      Pooled analyses suggest ground seed powder does more for LDL, while the oil does more for HDL.

    2. 2

      Take with food, split into two doses· Each dose

      Thymoquinone is lipophilic and absorbs better with dietary fat; splitting also reduces reflux and the strong aftertaste.

    3. 3

      Start at 1 g daily· Weeks 1-2

      Build to 2-3 g over two weeks if tolerated. Gastrointestinal upset is the usual limiting factor.

    4. 4

      Recheck lipids at 12 weeks· Week 12

      Use a fasting panel against a pre-treatment baseline; trial durations were typically 8 to 12 weeks.

    5. 5

      Buy on quality· Ongoing

      Cold-pressed, dark glass, in date, refrigerated after opening. Thymoquinone degrades with heat and light and content is rarely declared.

    It also lowers blood glucose

    The same trials that show lipid effects report reductions in fasting glucose and HbA1c. If you take glucose-lowering medication, monitor more closely when starting.

    Evidence

    The linked meta-analysis of Nigella sativa trials examined glycaemic control, lipid profiles and inflammatory and oxidative stress biomarkers together, and found improvements across several of them — the pattern that underpins this pairing's likely verdict. Reductions in total cholesterol and LDL are the most consistently reported lipid findings, with triglyceride effects somewhat smaller and HDL changes largely limited to oil preparations. What the evidence does not yet support is a claim about clinical outcomes. Trials measure biomarkers over weeks to a few months, in relatively small samples, with heterogeneous preparations, and there is no cardiovascular endpoint data. One study is linked to this pairing and listed below.

    A meta-analysis of Nigella sativa effects on glycaemic control, lipid profiles and inflammatory and oxidative stress biomarkers — the main evidence base behind this pairing.

    Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: A systematic review and meta-analysis of randomized controlled clinical trials

    Score: 7/10
    2020
    meta_analysis

    Hallajzadeh J, Milajerdi A, Mobini M +1 more

    Nigella sativa significantly reduced fasting glucose, HbA1c, total cholesterol and LDL cholesterol, while effects on HDL and inflammatory markers were inconsistent.

    View source
    Best available evidence
    Meta-analyses of small randomised trials in metabolic and diabetic populations
    Most consistent effect
    Lower total cholesterol and LDL
    Studied dose
    1-3 g oil or 1-2 g ground seed daily
    Time to effect
    8-12 weeks
    Certainty of evidence
    Low to moderate; preparation variability is the main limitation

    Safety

    Avoid in pregnancy

    Nigella sativa has demonstrated uterine-stimulating activity in animal studies and traditional use as an abortifacient. Avoid during pregnancy, and treat safety in breastfeeding as unestablished.

    Points to watch

    Nausea, reflux and stomach upset
    Contact dermatitis with topical use
    Additive blood glucose lowering
    Additive blood pressure lowering
    Case reports of liver enzyme elevation at high intake

    Interactions & Conflicts

    Interacts withSeverityMechanismAction
    Antidiabetic drugs (metformin, sulfonylureas, insulin)
    moderate
    		Additive glucose loweringMonitor glucose; dose adjustment may be needed
    Antihypertensives
    moderate
    		Additive blood pressure reductionMonitor readings when starting
    Warfarin and antiplatelets
    moderate
    		Possible platelet inhibitionMonitor INR or bleeding signs; discuss with a clinician
    CYP-metabolised drugs (ciclosporin, some statins)
    moderate
    		Thymoquinone inhibits several CYP enzymes in vitroAvoid with narrow-therapeutic-index drugs unless reviewed
    Sedatives
    low
    		Possible additive central depressant effect at high dosesUse caution when combining

    References

    1. Hallajzadeh J et al. Effects of Nigella sativa on glycemic control, lipid profiles, and biomarkers of inflammatory and oxidative stress: a systematic review and meta-analysis. Phytother Res. 2020
    2. Sahebkar A et al. A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with Nigella sativa on blood pressure. J Hypertens. 2016

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.